Latest
Eli Lilly touts additional Phase 3 results for retatrutide as it targets next-generation obesity and diabetes drugs
The company said updated findings from pivotal Phase 3 trials of retatrutide were presented this week, reinforcing enthusiasm around a potential triple-agonist approach to weight loss. Details beyond the headline-level results were not included in the cited post.
The Apex Times / Jun 7, 6:26 AM EDT / 1 min read
Read the brief